Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults

Hana Hakim, Kim J. Allison, Lee Ann Van De Velde, Yimei Li, Patricia M. Flynn, Jonathan Mccullers

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Influenza vaccination is recommended for immunocompromised patients. Methods: Children (6 months to 21 years) with cancer, HIV infection, or sickle cell disease (SCD) received 1 or 2 doses of pandemic 2009 H1N1 monovalent influenza vaccine (H1N1 MIV). Safety and tolerability, hemagglutination inhibition (HI) and microneutralization (MN) antibody titers were measured against 2009 H1N1 influenza A virus after each dose. Seroprotection (SP) and seroconversion (SC) rates were determined. Results: 103 participants were enrolled and 99 were evaluable (39 with HIV, 37 with cancer and 23 with SCD). Mean age (±SD) was 7.9 (±5.4) years for cancer participants, 18.0 (±3.5) for HIV, and 13.3 (±4.2) for SCD. 54% were males; 65% black; and 96% had received seasonal influenza vaccine. HIV-infected participants had a median CD4 count of 625cells/mm 3 (range, 140-1260). 46% had an undetectable HIV viral load and 41% were perinatally infected. No participant had vaccine-related serious adverse events. None developed influenza A proven illness during the 6 months after the vaccine. Local injection reactions were reported in 29% and systemic reactions in 42% after the first dose of vaccine. SC and SP were achieved after the last dose in 48% and 52%, respectively, of participants with leukemia or lymphoma, 50% and 75% of participants with solid tumors, 63% and 92% of HIV-infected participants, and 74% and 100% of participants with SCD. Conclusion: H1N1 MIV was safe and well tolerated. H1N1 MIV resulted in an adequate immune response in children with SCD. It was only modestly immunogenic in cancer or HIV participants.

Original languageEnglish (US)
Pages (from-to)879-885
Number of pages7
JournalVaccine
Volume30
Issue number5
DOIs
StatePublished - Jan 20 2012
Externally publishedYes

Fingerprint

Influenza Vaccines
young adults
sickle cell anemia
influenza
Sickle Cell Anemia
Young Adult
immune response
HIV
vaccines
Safety
neoplasms
Vaccines
Neoplasms
seroconversion
Human Influenza
dosage
H1N1 Subtype Influenza A Virus
Influenza A virus
Hemagglutination
Immunocompromised Host

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults. / Hakim, Hana; Allison, Kim J.; Van De Velde, Lee Ann; Li, Yimei; Flynn, Patricia M.; Mccullers, Jonathan.

In: Vaccine, Vol. 30, No. 5, 20.01.2012, p. 879-885.

Research output: Contribution to journalArticle

Hakim, Hana ; Allison, Kim J. ; Van De Velde, Lee Ann ; Li, Yimei ; Flynn, Patricia M. ; Mccullers, Jonathan. / Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults. In: Vaccine. 2012 ; Vol. 30, No. 5. pp. 879-885.
@article{5258da0b949a4005a9313f580758b3ed,
title = "Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults",
abstract = "Background: Influenza vaccination is recommended for immunocompromised patients. Methods: Children (6 months to 21 years) with cancer, HIV infection, or sickle cell disease (SCD) received 1 or 2 doses of pandemic 2009 H1N1 monovalent influenza vaccine (H1N1 MIV). Safety and tolerability, hemagglutination inhibition (HI) and microneutralization (MN) antibody titers were measured against 2009 H1N1 influenza A virus after each dose. Seroprotection (SP) and seroconversion (SC) rates were determined. Results: 103 participants were enrolled and 99 were evaluable (39 with HIV, 37 with cancer and 23 with SCD). Mean age (±SD) was 7.9 (±5.4) years for cancer participants, 18.0 (±3.5) for HIV, and 13.3 (±4.2) for SCD. 54{\%} were males; 65{\%} black; and 96{\%} had received seasonal influenza vaccine. HIV-infected participants had a median CD4 count of 625cells/mm 3 (range, 140-1260). 46{\%} had an undetectable HIV viral load and 41{\%} were perinatally infected. No participant had vaccine-related serious adverse events. None developed influenza A proven illness during the 6 months after the vaccine. Local injection reactions were reported in 29{\%} and systemic reactions in 42{\%} after the first dose of vaccine. SC and SP were achieved after the last dose in 48{\%} and 52{\%}, respectively, of participants with leukemia or lymphoma, 50{\%} and 75{\%} of participants with solid tumors, 63{\%} and 92{\%} of HIV-infected participants, and 74{\%} and 100{\%} of participants with SCD. Conclusion: H1N1 MIV was safe and well tolerated. H1N1 MIV resulted in an adequate immune response in children with SCD. It was only modestly immunogenic in cancer or HIV participants.",
author = "Hana Hakim and Allison, {Kim J.} and {Van De Velde}, {Lee Ann} and Yimei Li and Flynn, {Patricia M.} and Jonathan Mccullers",
year = "2012",
month = "1",
day = "20",
doi = "10.1016/j.vaccine.2011.11.105",
language = "English (US)",
volume = "30",
pages = "879--885",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults

AU - Hakim, Hana

AU - Allison, Kim J.

AU - Van De Velde, Lee Ann

AU - Li, Yimei

AU - Flynn, Patricia M.

AU - Mccullers, Jonathan

PY - 2012/1/20

Y1 - 2012/1/20

N2 - Background: Influenza vaccination is recommended for immunocompromised patients. Methods: Children (6 months to 21 years) with cancer, HIV infection, or sickle cell disease (SCD) received 1 or 2 doses of pandemic 2009 H1N1 monovalent influenza vaccine (H1N1 MIV). Safety and tolerability, hemagglutination inhibition (HI) and microneutralization (MN) antibody titers were measured against 2009 H1N1 influenza A virus after each dose. Seroprotection (SP) and seroconversion (SC) rates were determined. Results: 103 participants were enrolled and 99 were evaluable (39 with HIV, 37 with cancer and 23 with SCD). Mean age (±SD) was 7.9 (±5.4) years for cancer participants, 18.0 (±3.5) for HIV, and 13.3 (±4.2) for SCD. 54% were males; 65% black; and 96% had received seasonal influenza vaccine. HIV-infected participants had a median CD4 count of 625cells/mm 3 (range, 140-1260). 46% had an undetectable HIV viral load and 41% were perinatally infected. No participant had vaccine-related serious adverse events. None developed influenza A proven illness during the 6 months after the vaccine. Local injection reactions were reported in 29% and systemic reactions in 42% after the first dose of vaccine. SC and SP were achieved after the last dose in 48% and 52%, respectively, of participants with leukemia or lymphoma, 50% and 75% of participants with solid tumors, 63% and 92% of HIV-infected participants, and 74% and 100% of participants with SCD. Conclusion: H1N1 MIV was safe and well tolerated. H1N1 MIV resulted in an adequate immune response in children with SCD. It was only modestly immunogenic in cancer or HIV participants.

AB - Background: Influenza vaccination is recommended for immunocompromised patients. Methods: Children (6 months to 21 years) with cancer, HIV infection, or sickle cell disease (SCD) received 1 or 2 doses of pandemic 2009 H1N1 monovalent influenza vaccine (H1N1 MIV). Safety and tolerability, hemagglutination inhibition (HI) and microneutralization (MN) antibody titers were measured against 2009 H1N1 influenza A virus after each dose. Seroprotection (SP) and seroconversion (SC) rates were determined. Results: 103 participants were enrolled and 99 were evaluable (39 with HIV, 37 with cancer and 23 with SCD). Mean age (±SD) was 7.9 (±5.4) years for cancer participants, 18.0 (±3.5) for HIV, and 13.3 (±4.2) for SCD. 54% were males; 65% black; and 96% had received seasonal influenza vaccine. HIV-infected participants had a median CD4 count of 625cells/mm 3 (range, 140-1260). 46% had an undetectable HIV viral load and 41% were perinatally infected. No participant had vaccine-related serious adverse events. None developed influenza A proven illness during the 6 months after the vaccine. Local injection reactions were reported in 29% and systemic reactions in 42% after the first dose of vaccine. SC and SP were achieved after the last dose in 48% and 52%, respectively, of participants with leukemia or lymphoma, 50% and 75% of participants with solid tumors, 63% and 92% of HIV-infected participants, and 74% and 100% of participants with SCD. Conclusion: H1N1 MIV was safe and well tolerated. H1N1 MIV resulted in an adequate immune response in children with SCD. It was only modestly immunogenic in cancer or HIV participants.

UR - http://www.scopus.com/inward/record.url?scp=84855453134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855453134&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2011.11.105

DO - 10.1016/j.vaccine.2011.11.105

M3 - Article

VL - 30

SP - 879

EP - 885

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 5

ER -